Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.
about
Neointimal expression of rapamycin receptor FK506-binding protein FKBP12: postinjury animal and human in-stent restenosis tissue characteristicsSirolimus-eluting stents for treatment of in-stent restenosis: immediate and late resultsActivity of sirolimus in patients with myelodysplastic syndrome--results of a pilot study.Smooth muscle-specific drug targets for next-generation drug-eluting stentTwo-year clinical outcomes of patients with long segments drug-eluting stents: comparison of sirolimus-eluting stent with paclitaxel-eluting stentSirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II).Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry.Long term outcome after intracoronary beta radiation therapy.Drug-eluting stents: new era and new concerns.Anti-monocyte chemoattractant protein-1 gene therapy for cardiovascular diseases.Pulmonary vein stenosis: initial experience with cutting balloon angioplasty.Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease.Novel therapies for hemodialysis vascular access dysfunction: fact or fiction!Identification and characterization of [6]-shogaol from ginger as inhibitor of vascular smooth muscle cell proliferation.An evidence-based approach to the use of drug-eluting stents in clinical practice.In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach.In vivo Evaluation of Cenderitide-Eluting Stent (CES) II.A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis.Update on stents: recent studies on the TAXUS stent system in small vessels.The association between kidney function, coronary artery disease, and clinical outcome in patients undergoing coronary angiographyCTP synthase 1, a smooth muscle-sensitive therapeutic target for effective vascular repairNanotechnology in interventional cardiology.Nitric oxide-dependent bone marrow progenitor mobilization by carbon monoxide enhances endothelial repair after vascular injurySerial changes of neointimal tissue after everolimus-eluting stent implantation in porcine coronary artery: an optical coherence tomography analysis.Treating multivessel disease in the era of coated stents: introduction.An optical coherence tomography study of a biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study.Long-term clinical outcomes after unprotected left main coronary artery stenting in an all-comers patient population.Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis.Paclitaxel eluting stents for the treatment of angiographically non-significant atherosclerotic lesions.Angioscopy study from a large patient population comparing sirolimus-eluting stent with biodegradable versus durable polymer.Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6- and 18-month follow-up.Paclitaxel-eluting composite fibers: drug release and tensile mechanical properties.Dollars and stents: the economics of drug-eluting stents.Translation in cardiovascular stents and occluders: From biostable to fully degradable.Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation.
P2860
Q24298705-5B4C8202-FBD0-4CBF-93E3-FBDE4AA70A19Q28175715-AF2887F3-1CCC-46FA-8AA6-ACBFB6DF8478Q33365126-07572FDA-EB18-434F-931D-CC54984C97BAQ35173060-D146AEE9-78B1-4349-8365-DEF112E6D2AFQ35333704-64236E4F-FB7A-44A0-BE94-022C69F90DF9Q35582847-768319DF-A10D-42DD-B38C-F180FD45327CQ35583034-D93AB8E4-1B62-4BFB-BB09-C678834008CFQ35584438-D0FADAB6-8F07-4AEF-B252-1C983F0819FAQ35647727-DD61A280-AA8E-4971-B47D-53E5A73C70FEQ35696305-5F2A676E-A9FE-4232-880C-28FE7542493EQ35770926-51FF3744-B6B5-4D61-8C5C-3B0F1616A291Q35925484-A48C755B-2121-4001-AB80-9EA6933E017DQ35938663-9A630762-1B1D-4E67-8FD7-91DC9ACC19D9Q35945466-77DE70FA-9C37-4482-A601-34D21CD2F78FQ35997659-D263AEB9-1C76-493D-8320-9A9135BA4725Q36069458-5E6B714F-94AD-4600-B677-8A0C2EC6291EQ36086606-19CB8452-EEE3-48D5-BFD5-823F7AED8AE6Q36206241-DC46F964-B697-47A9-AB89-C82BFB513690Q36470750-66B846F3-9D2F-4203-8330-FF52E8768876Q36488244-877D3FBF-247B-47BF-B66E-67636E1128EBQ36917389-46E77525-F638-4417-88E8-E144E2C0BF77Q36985317-9F5BAF6D-18FD-4566-AA10-C3193F649ACEQ37078155-F58E5AFD-B18E-4879-B4EE-C93689DE700DQ37367271-001F973B-501F-4650-A0EA-F6F7367FF6C7Q37900267-EFFA9588-DC35-478C-8F0B-517A29ECF8B5Q39691556-425AEF71-9A39-44C8-AEE9-7C7BFD125AE0Q41981596-8CEFD953-0900-4C17-8E08-2634769FD630Q42123214-905FB5EC-0682-45C9-8F99-7F7DA0948EF3Q43248483-7345F147-CC50-47D3-906E-F0D0F2ADADE6Q44583074-9C0B6B18-827E-4E9E-8086-FC28527023C2Q44639133-906094CB-57BE-4917-B982-7ECCC9FFEAC0Q46644197-2B4CDE42-6203-4185-8615-0D64D21C83C1Q50525494-B7F232FD-98D0-4912-A234-3BEFF27997E8Q50541778-20C3C9AA-76FA-419C-B7C3-30D5A36B5076Q50962970-22D5B27F-159D-4620-89CA-D94F7B886830Q51484880-49135FA1-4CD1-4C23-B2EC-7B60D2C9DA69Q52724991-61D17B5A-1268-4D23-B618-23D4658D2518Q53629903-560BA228-104E-432C-9CC6-71770FEB3632
P2860
Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Persistent inhibition of neoin ...... vascular ultrasound follow-up.
@en
Persistent inhibition of neoin ...... vascular ultrasound follow-up.
@nl
type
label
Persistent inhibition of neoin ...... vascular ultrasound follow-up.
@en
Persistent inhibition of neoin ...... vascular ultrasound follow-up.
@nl
prefLabel
Persistent inhibition of neoin ...... vascular ultrasound follow-up.
@en
Persistent inhibition of neoin ...... vascular ultrasound follow-up.
@nl
P2093
P1433
P1476
Persistent inhibition of neoin ...... vascular ultrasound follow-up.
@en
P2093
David P Foley
Evelyn Regar
Jeroen Vos
Kengo Tanabe
Marcel van den Brand
Muzaffer Degertekin
Peter C Smits
Pim de Feyter
Wim J van der Giessen
P304
P356
10.1161/01.CIR.0000034447.02535.D5
P407
P577
2002-09-01T00:00:00Z